Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Death or cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Mortality Mortality at latest · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids showed no clear difference in mortality at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
BPD (36 weeks' PMA) · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids probably leads to lower BPD (36 weeks' PMA) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to lower mortality or BPD at 36 weeks' PMA compared with placebo or no treatment (high certainty).
1 finding from 1 review
Gastrointestinal perforation during primary hospitalisation · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to higher gastrointestinal perforation during primary hospitalisation compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to higher cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
Death or cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids showed no clear difference in mortality or cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
Treatment failure To discharge · newborn infants with opioid withdrawal
It is very uncertain whether opioid changes treatment failure To discharge compared with placebo or no treatment / usual care (very low certainty).
1 finding from 1 review
Seizures To discharge · newborn infants with opioid withdrawal
1 finding from 1 review
Neonatal or infant mortality · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurodevelopmental disability · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · newborn infants with opioid withdrawal
1 finding from 1 review
Days treatment · newborn infants with opioid withdrawal
1 finding from 1 review
Adverse events (treatment related) To discharge · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of oxygen therapy (hours) · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Need for continuous positive airway pressure (yes/no) · patients with the management of transient tachypnea of the newborn
It is very uncertain whether salbutamol changes need for continuous positive airway pressure (yes/no) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Need for mechanical ventilation · patients with the management of transient tachypnea of the newborn
It is very uncertain whether salbutamol changes need for mechanical ventilation (yes/no) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Duration of respiratory support (intermittent positive pressure ventilation or continuous positive airway pressure; hours). · patients with the management of transient tachypnea of the newborn
1 finding from 1 review